Experimental medicine in psychiatry
The DOI matches its Crossref record.
Abstract
The recent allocation of £15 million by the MRC (Medical Research Council) specifically to support research in experimental medicine (defined as the ‘Investigation undertaken in human beings to identify mechanisms of pathophysiology or disease, or to test the validity and importance of new discoveries or treatments, relating where appropriate to model systems’) underlines the priority currently given to this area of research. The recent interest in experimental, sometimes called ‘translational’ medicine suggests that it is something new. However, the BAP (British Association Psychopharmacology) was established in 1974 to support experimental and translational medicine in the area of psychopharmacology by bringing together the preclinical and clinical arms of this research area. Through its meetings and journal the BAP has been at the forefront of translational medicine in its purest form – combining the knowledge gathered from preclinical and clinical science to provide synergy in the search for new treatments for some of the most devastating disorders known to man. Indeed it is difficult to name a society that does more to put the ‘translational’ into ‘translational medicine’ than the BAP and we have little doubt that psychopharmacology alone could generate world class research proposals that would account for all of the MRC allocation. Another strong supporter of translational medicine is the pharmaceutical industry. Its driving force has been the large markets in psychiatry for medicines such as Risperidone (>$2 billion annual sales) for the treatment of schizophrenia or Duloxetine (>$1 billion annual sales) for depression. Consequently pharmaceutical companies have poured significant resources into discovering and developing new treatments for psychiatric disorders. On the preclinical side of the translational medicine equation, the combined resources of academia and industry have resulted in a phenomenal increase in fundamental knowledge, new experimental techniques and, indeed, whole new classes of candidate compounds. However, clinical translation of these findings directly to benefit psychiatric patients has so far been very limited and most of the medicines we think of as new – the atypical antipsychotics or the SSRIs (Selective Serotonin Reuptake Inhibitors), for example – were conceived as refinements of classical treatments. The failure, so far, of genuine innovation has been disappointing, and so merits closer examination. For example, preclinical and early clinical studies suggested that NK-1 antagonists would be effective antidepressants. The first clinical study was also positive, but subsequent large Phase III studies were not. Uncertainty about the clinical efficacy of the compounds led to the termination of investment by the leading player. Unfortunately, placebo controlled trials in depression are difficult to conduct in patients with significant severity of depression, and placebo response rates are high so confounding detection of positive treatment effects. Such trials are also extremely expensive. Very promising candidate medicines may founder because of chance effects in very expensive clinical studies. There is an evident gap between the preclinical portfolio and such large scale clinical trials. The question is whether we can harness and exploit the strong clinical science base in the UK to fill this gap by generating translational data for new compounds, which would be highly predictive of subsequent clinical utility. There should be no doubt about the unmet needs of the patients. Economically, more beds are occupied by patients with psychiatric disorders than any other patient group; schizophrenia alone costs the National Health Service in England and Wales about £2.9 billion each year. Add in the cost of lost working hours and benefit payments (about 95% of patients with schizophrenia are unemployed) the overall costs rocket. Thus, it would be foolish to doubt the potential benefits of investing in CNS (Central Nervous System) research and development. The existing global market for CNS drugs for 12 months to March 2004 was $59.6 billion and with a 14% increase on the 12 months to March 2003 was the second fastest growing therapeutic category. Unfortunately, the costs of drug development (including lost opportunity costs) continue to spiral and the average cost of development of a new drug is estimated to be about $900 million. Furthermore, the chance of success of a novel compound in Phase 1 reaching the market is 11% for all therapeutic categories and only 8% for CNS disorders. This makes the costs of CNS drug development particularly high and raises the question of why it is more difficult to discover and develop drugs for CNS disorders and why the success rate is not improving (Kola and Landis, 2004). In the past 10 years there has been little improvement in the overall rate of novel compounds in development but there have been significant changes in the causes of attrition
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The impact of anxiety upon cognition: perspectives from human threat of shock studies
Robinson, O. J., Vytal, K., Cornwell, B. R., & Grillon, C. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00203 · Cited by 613
“A serious impediment to bringing candidate anxiolytics to the marketplace is the lack of effective models to screen drugs (Rodgers, 1997; Kola and Landis, 2004; Dawson and Goodwin, 2005).”
BackgroundEffect of Acute Antidepressant Administration on Negative Affective Bias in Depressed Patients
Harmer, C. J., O’Sullivan, U., Favaron, E., Massey-Chase, R., Ayres, R., Reinecke, A., Goodwin, G. M., & Cowen, P. J. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020149 · Cited by 485
Self-citationEfficacy markers in depression
Harmer, C. J., Cowen, P. J., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110367722 · Cited by 122
“Historically, the development of new treatments for depression often failed because of problems with chemical structure or brain penetrance of compounds (Dawson and Goodwin, 2005).”
BackgroundSelf-citationAgomelatine facilitates positive versus negative affective processing in healthy volunteer models
Harmer, C. J., de Bodinat, C., Dawson, G. R., Dourish, C. T., Waldenmaier, L., Adams, S., Cowen, P. J., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110376689 · Cited by 77
Self-citationNK 1 receptor antagonism and emotional processing in healthy volunteers
Chandra, P., Hafizi, S., Massey-Chase, R., Goodwin, G., Cowen, P., & Harmer, C. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109103101 · Cited by 30
Self-citation
Metadata
- Authors
- Dawson, G. R., & Goodwin, G.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2005-11
- Volume
- 19
- Issue
- 6
- Pages
- 565-566
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2069236946
- Cited by
- 17
- References
- 0
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Experimental medicine in psychiatry. https://app.cochat.ai/papers/10.1177/0269881105059935
- The paper
- Dawson, G. R., & Goodwin, G. (2005). Experimental medicine in psychiatry. Journal of Psychopharmacology. https://doi.org/10.1177/0269881105059935
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.